INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-964-3720
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
Next Earnings Date2/28/2020 (Estimated)
OptionableNot Optionable
INmune Bio (NASDAQ:INMB) Frequently Asked Questions
What is INmune Bio's stock symbol?
INmune Bio trades on the NASDAQ under the ticker symbol "INMB."
How were INmune Bio's earnings last quarter?
INmune Bio Inc (NASDAQ:INMB) released its earnings results on Friday, November, 8th. The company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.09. View INmune Bio's Earnings History.
When is INmune Bio's next earnings date?
What price target have analysts set for INMB?
3 brokers have issued 1-year target prices for INmune Bio's stock. Their forecasts range from $11.00 to $13.00. On average, they anticipate INmune Bio's share price to reach $12.33 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price. View Analyst Price Targets for INmune Bio.
What is the consensus analysts' recommendation for INmune Bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for INmune Bio.
What are Wall Street analysts saying about INmune Bio stock?
Here are some recent quotes from research analysts about INmune Bio stock:
- 1. HC Wainwright analysts commented, "We maintain our Buy rating of INMB and our 12-month price target of $11.50 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from 2030, assuming a 13% discount rate and a 0.5% terminal growth rate. We derive an rNPV of $345M for the products and add in cash and cash equivalents of $9.4M to arrive at a 12-month price target of $11.43 per diluted share, which we round to $11.50." (9/12/2019)
- 2. Maxim Group analysts commented, "INmune Bio reported 2Q19 with operating expenses of ~$2M, partially offset by a $1.5M non-cash charge (waiver of common stock issuable); net loss was ($0.4M). The company ended the period with $9.4M in cash on the balance sheet. In addition, recall that as a result of the $1M grant from the Alzheimer’s foundation and also conducting trials abroad which comes with significant R&D reimbursement, the runway is further extended." (8/14/2019)
Has INmune Bio been receiving favorable news coverage?
Media headlines about INMB stock have been trending very negative on Sunday, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. INmune Bio earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for INmune Bio.
Are investors shorting INmune Bio?
INmune Bio saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 15,600 shares, a decline of 17.5% from the January 15th total of 18,900 shares. Based on an average trading volume of 19,000 shares, the short-interest ratio is presently 0.8 days. Approximately 0.8% of the shares of the company are sold short. View INmune Bio's Current Options Chain.
Who are some of INmune Bio's key competitors?
Some companies that are related to INmune Bio include La Jolla Pharmaceutical (LJPC), LogicBio Therapeutics (LOGC), Verona Pharma (TARA), CASI Pharmaceuticals (CASI), Jounce Therapeutics (JNCE), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Brainstorm Cell Therapeutics (BCLI), Solid Biosciences (SLDB), Dyadic International (DYAI), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Gamida Cell (GMDA), Axcella Health (AXLA) and Cidara Therapeutics (CDTX).
What other stocks do shareholders of INmune Bio own?
Who are INmune Bio's key executives?
INmune Bio's management team includes the folowing people:
- Dr. Raymond Joseph Tesi, Co-Founder, Pres, CEO & Director (Age 63)
- Mr. David J. Moss M.B.A., CFO, Treasurer & Sec. (Age 49)
- Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Chief Scientific Officer (Age 56)
How do I buy shares of INmune Bio?
Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is INmune Bio's stock price today?
One share of INMB stock can currently be purchased for approximately $5.22.
How big of a company is INmune Bio?
What is INmune Bio's official website?
How can I contact INmune Bio?
INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at 858-964-3720 or via email at [email protected]
MarketBeat Community Rating for INmune Bio (NASDAQ INMB)
MarketBeat's community ratings are surveys of what our community members think about INmune Bio and other stocks. Vote "Outperform" if you believe INMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
